{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8"},{"groupId":"OG001","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.","groups":[{"description":"Pomalidomide: Comparison of different dosages and schedules of drug","id":"OG000","title":"Pomalidomide 2 mg/d on 28 Days/28 Day Cycle"},{"description":"Pomalidomide: Comparison of different dosages and schedules of drug","id":"OG001","title":"Pomalidomide 4 mg/d on 21 Days/28 Day Cycle"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days)","title":"Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}